Abraxis BioScience, Inc. (Acquired by Celgene Corporation)

171 articles about Abraxis BioScience, Inc. (Acquired by Celgene Corporation)

• Abraxis BioScience, Inc. Announces Date for 2008 First Quarter Financial Results and Investor Conference Call

  5/13/2008

• Abraxis BioScience, Inc. Reports Promising Clinical Data in Advanced Pancreatic Cancer Using a Combination of nab-Paclitaxel (ABRAXANE(R)) and Gemcitabine (Gemzar(R))

  4/23/2008

• Abraxis BioScience, Inc. Presents New Preclinical Data Demonstrating Eradication of Large Orthotopic Breast Tumors and Metastasis with Combined nab-Paclitaxel (ABRAXANE(R)) and Bevacizumab (Avastin(R)) Therapy

  4/15/2008

• Abraxis BioScience, Inc. Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea

  4/9/2008

• Abraxis BioScience, Inc. Acquires Shimoda Biotech and Platco Technologies

  4/4/2008

• Abraxis BioScience, Inc. Initiates Patient Enrollment in Phase II Study of Coroxane(TM) for Prevention of Restenosis in Peripheral Vascular Disease

  4/2/2008

• Abraxis BioScience, Inc. Reports 83% Revenue Growth to a Record $334 Million for 2007

  4/1/2008

• Abraxis BioScience, Inc. Announces Dates for 2007 Year-End Financial Results and Investor Conference Call

  3/28/2008

• Abraxis BioScience, Inc. Announces Filing of Marketing Application in Japan for ABRAXANE in the Treatment of Breast Cancer

  3/17/2008

• Abraxis BioScience, Inc. Establishes Global Leadership Team

  2/7/2008

• Abraxis BioScience, Inc. Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe

  1/22/2008

• Abraxis BioScience, Inc. Announces Agreement with Green Cross for the Commercialization of ABRAXANE in Korea

  11/28/2007

• Abraxis BioScience, Inc. to Present at Lazard Markets Healthcare Conference

  11/27/2007

• Abraxis BioScience, Inc. Emerges as a Stand-Alone Proprietary Biotechnology Company

  11/14/2007

• Abraxis BioScience, Inc. Reports an Increase in Third Quarter Revenue of 19 Percent to $241 Million versus $203 Million in Prior Year Period

  11/8/2007

• Abraxis BioScience, Inc. Announces the Closing Date for the Separation of Its Proprietary Business from Its Hospital-Based Business

  11/8/2007

• Abraxis BioScience, Inc. Announces Record and Distribution Date in Connection with the Separation of Its Businesses

  11/8/2007

• Abraxis BioScience, Inc. Announces Date for Third Quarter Financial Results and Investor Conference Call

  10/26/2007

• Abraxis BioScience, Inc. and BioCon Limited Announce Approval of ABRAXANE in India for the Treatment of Breast Cancer

  10/18/2007

• Abraxis BioScience, Inc. Reaches Agreement with the FDA Following Special Protocol Assessment for Phase III Trial of ABRAXANE in Non-Small Cell Lung Cancer

  10/15/2007